A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine Trulicity.
Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback